Affinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung technology ...

OAK BROOK, Ill. – An artificial intelligence (AI) deep learning tool that estimates the malignancy risk of lung nodules achieved high cancer detection rates while significantly reducing false-positive ...

Talk about a breath of fresh air. Researchers have developed a groundbreaking device that may one day make detecting lung cancer as easy as exhaling. “We built a screening tool that could allow ...

Survival outcomes in non-small cell lung cancer: Real-world analysis of immunotherapy era vs pre-immunotherapy era, with insights into treatment settings, racial disparities, and socioeconomic impacts ...

The next breakthrough in cancer screening is emerging from the convergence of artificial intelligence and canine biology. That’s the thesis behind SpotitEarly, a startup that recently launched in the ...

Affinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy ...

Lung cancer symptoms are often non-specific, leading to late detection and misattribution to less severe conditions. The GO2 for Lung Cancer provides resources, policy advocacy, and access to clinical ...